Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D Grade, GMP Grade), By Application, By Development Phase, By Region, And Segment Forecasts, 2024 - 2030

Research Methodology

A three-pronged approach was followed for deducing the plasmid dna manufacturing market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for plasmid dna manufacturing market to gather the most reliable and current information possible.

• We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
• We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
• We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
• We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
• We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of plasmid dna manufacturing market data depending on the type of information we’re trying to uncover in our research.

• Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

• Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

• Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

• Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

• Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

• Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

• This step also entails the finalization of the report scope and data representation pattern.

• Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Plasmid DNA Manufacturing Market Categorization:

The plasmid dna manufacturing market was categorized into four segments, namely grade (R&D Grade, GMP Grade), development phase (Pre-Clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics), application (DNA Vaccines, Cell & Gene Therapy, Immunotherapy), disease (Infectious Disease, Cancer, Genetic Disorder), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The plasmid dna manufacturing market was segmented into grade, development application, disease, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

• Demand estimation of each product across countries/regions summed up to from the total market.

• Variable analysis for demand forecast.

• Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

• Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

• Used extensively for new product forecasting or analyzing penetration levels.

• Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

• Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

• This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The plasmid dna manufacturing market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; Germany; U.K.; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Plasmid dna manufacturing market companies & financials:

The plasmid dna manufacturing market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

• Charles River Laboratories, headquartered in Massachusetts, U.S., is one of the leading providers of drug discovery and development services. It was founded in 1947 and has a global presence with a strong distribution network across the globe. It had an employee strength of over 20,000 in 2021. The company is divided into three divisions: research models & services, discovery & safety assessment, and manufacturing solutions. The company's services business & research model, which produces and ships animal research models with certain genetic traits, for pre-clinical investigations all over the world is one of the industry leaders in providing animal models for research laboratory testing. The discovery and safety assessment segment offers the services necessary to advance medicine through its early stages of development, such as discovery services.

• Cognate Bioservices is a pharmaceutical developer & contract manufacturer for the global cellular treatments market. Through scientific and management experience, the company offers contract development & manufacturing services to pharmaceutical firms, aiding companies and institutes engaged in the development and manufacture of cell-based medicines with full development & Current GMP (cGMP) manufacturing services.

• Vigene Biosciences, Inc. is a supplier of viral vector-based gene delivery products and services for research and clinical purposes. The model has allowed innovators in the cell and gene therapy industry to create and market effective cell as well as gene therapies, diagnostics, vaccines, and healthcare products by providing integrated services, cutting-edge gene delivery technology, and manufacturing solutions.

• VGXI, Inc. is a Contract Manufacturing Organization (CMO) established in 1997 and headquartered in Texas, U.S. The company operates under GeneOne Life Science, Inc., an R&D organization operating in the gene-based biomedicine space. VGXI deals with contract manufacturing of DNA plasmids. The company’s production services involve cGMP DNA plasmids manufacturing for commercial & clinical supply, highly documented DNA plasmids for toxicology studies & virus production, and production of high-purity plasmid DNA for pre-clinical research.

• Lonza is a worldwide supplier of biopharmaceuticals and offers products in bioresearch, consumer care, agro ingredients, pharmaceutical & biotechnology, water treatment, industrial solutions, and wood protection. The company was founded in 1897 and is headquartered in Basel, Switzerland, with an employee strength of 16,540 as of 2020. The company’s market is segmented into pharma & biotech and specialty ingredients. In March 2009, the company joined the United Nations Global Compact as a strategic initiative to enhance its business. Lonza has operations in North America, Europe, Asia, and other regions, with more than 100 sites and offices across the globe. The company focused its efforts on reorganizing its emerging technologies business in 2017, owing to rapid growth in global cell & gene therapies research. It has four global centers of excellence in cell & gene therapy in Singapore, Portsmouth (U.S.), Maastricht/Geleen (NL), and Houston (U.S.).

• Danaher designs, manufactures and commercializes products as well as services catering to medical, professional, & commercial applications. The company operates through four segments: diagnostics, life sciences, environmental & applied solutions, and dental solutions. Danaher’s diagnostics segment offers reagents, analytical instruments, software, consumables, and services for physicians’ offices, hospitals, reference laboratories, and other critical care settings to diagnose various diseases. Danaher’s facilities are located in more than 60 countries across the world. The company offers products across immunohistochemistry, digital pathology; surgery, clinical microscopy, in situ hybridization, and radiology, along with FISH & histology equipment & consumables.

• Kaneka Eurogentec S.A. supports researchers working on life science projects, molecular diagnostics, & therapeutic advancements by providing them with products and services. This helps improve health and battle diseases. The Liège-based business is a reputable CDMO for bioproduction of vaccines, pharmaceuticals, & medicines and is also one of the leading suppliers in the fields of genomics and proteomics. In addition, it is one of the market leaders in the mass development of GMP pDNA for DNA vaccines & vector-based gene therapies. Kaneka Eurogentec provides CDMO assistance for GMP mRNA, the main component of RNA-based vaccines and gene therapies.

• Cell and Gene Therapy Catapult is a developer of cell and gene treatments platform designed to aid in the translation of early-stage research into economically viable & investable cures. The company's therapeutics platform provides a cutting-edge method for refurbishing products and reducing their risk for more investment. It also offers infrastructure and clinical & technological skills, enabling research groups to complete full-scale commercialization. It had an employee strength of around 350 in 2021.

• VectorBuilder Inc. is a developer of a digital platform for custom cloning, library creation, virus packaging, and cell line development. In addition to offering other molecular biology services like library construction, recombineering, and mutagenesis, the company's web-based system provides unified data management that contains all the vectors, orders, & technical inquiries created by consumers in their records and features unique identifiers as well as permanent URLs (uniform resource locator). This enables researchers to retrieve as well as share any vectors they structured easily and securely.

• Eurofins Genomics is a provider of genomic services aimed at laying the groundwork for a deeper comprehension of genetic influences on health and well-being. The company's services are primarily focused on providing sequencing, genotyping, gene expression, customized DNA sequencing, oligonucleotides, siRNA, and gene synthesis, allowing customers to access pharma, diagnostics, agricultural, food, and biotechnology services at a competitive price.

Value chain-based sizing & forecasting

Supply Side Estimates

• Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

• Segment revenue determination via variable analysis and penetration modeling.

• Competitive benchmarking to identify market leaders and their collective revenue shares.

• Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

• Identifying parent markets and ancillary markets

• Segment penetration analysis to obtain pertinent

• revenue/volume

• Heuristic forecasting with the help of subject matter experts

• Forecasting via variable analysis

Plasmid DNA Manufacturing Market Report Objectives:

• Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

• Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

• Understanding market estimates and forecasts (with the base year as 2023, historic information from 2018 - 2022, and forecast from 2024 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Plasmid DNA Manufacturing Market Report Assumptions:

• The report provides market value for the base year 2023 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

• The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

• We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

• All market estimates and forecasts have been validated through primary interviews with the key industry participants.

• Inflation has not been accounted for to estimate and forecast the market.

• Numbers may not add up due to rounding off.

• Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

• Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

• Latin America includes Central American countries and the South American continent

• Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

• Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

• Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.